Top 10 Pharma Drug Discovery Delivery Capital Raises and Investors in the U.S. – September 16th – 30th, 2025

Several interesting transactions closed in the Pharma Drug Discovery Delivery sector over the past two weeks. If you would like more info on these deals or would like to discuss the capital raising market for your company, please contact me.

PIPE

1. 1. Belite Bio, a clinical-stage biopharmaceutical drug development company for novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, received approximately $125 million of development capital from Soleus Capital, RA Capital Management, Eventide Asset Management, Vestal Point Capital, RTW Investments and Marshall Wace.
   2. SureNano Science, a nanotechnology supply company with the license to sell and otherwise commercialize the SureNanoTM surfactant (the SureNano Surfactant) in Canada and Colorado, received CAD 160,000 of development capital.

Merger/Acquisition and Corporate

3. 3. Studymetrix Research, a clinical research service for advancing medical science through human studies, was acquired by East Coast Institute For Research, via its financial sponsor Gauge Capital, through an LBO.
   4. Theratechnologies, a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients, was acquired by Future Pak, a subsidiary of Woodward Pharma Services, for approximately $254 million.

Later Stage VC

5. 5. Ensoma, a biotech company that develops genomic medicine in vivo approach to engineer any or all blood and immune cells to cure diseases, raised $53 million of venture funding from Gilead Sciences, Delos Capital and Cormorant Asset Management.
   6. Balanced Pharma, pharmaceutical drugs that enhances patient comfort and safety, raised $3.2 million of venture funding.

Early Stage VC

7. 7. Crossbow Therapeutics, a biotechnology company that enhances the quality of life for individuals suffering from cancer, raised Series B venture.
   8. Tasca Therapeutics, a biotechnology company that develops small molecule drugs for hard-to-treat oncology indications, raised $67 million of Series A venture funding in a deal led by Regeneron Ventures and Cure Ventures.

Accelerator/Incubator

9. 9. Auxilium Health, a biotechnology research company that develops wound care technology, joined Bounce Innovation Hub as a part of its Synthe6 Materials Accelerator cohort and received $25,000 in funding in the form of grant.

Seed Round

10. 10. FYR Diagnostics, a biomarker detection technology that tackles burdensome diseases in human healthcare and agriculture with large unmet clinical needs, raised $8 million through the combination of Seed-2A, Seed-2B and Seed-2C funding from Two Bear Capital, Yuvaan Tiwari Foundation and The Sontag Foundation.

#castleplacement #capitalraising #privateequity #venturecapital #investment #pharmadrugdiscovery #pharmadrugdelivery

Dianna Rudy

Managing Director

Please contact me if you have any questions or would like to discuss your capital raise:

Email: druddy@castleplacement.com

(C) (406) 868-3218

Send us a message:

Name *

First

Last

Message Your Email

Email *

Your Message *

Message Us Now